tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Alkermes initiated with a Buy at Goldman Sachs

Goldman Sachs initiated coverage of Alkermes (ALKS) with a Buy rating and $43 price target The firm says the company’s “mature” portfolio of neuropsych assets are on track to achieve fiscal 2025 guidance while its orexin receptor 2 portfolio updates will drive share appreciation. Goldman is optimistic on the shares into the upcoming data.

Elevate Your Investing Strategy:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1